Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C21H20N4O3
Numéro CAS:
Poids moléculaire :
376.41
NACRES:
NA.83
PubChem Substance ID:
UNSPSC Code:
12352204
EC Number:
251-245-7
MDL number:
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderassay
≥98%
Quality Level
form
powder
solubility
ethanol: 50 mg/mL, clear, colorless to light yellow
SMILES string
COc1ccc(cc1C(=O)NCc2cccnc2)C(=O)NCc3cccnc3
InChI
1S/C21H20N4O3/c1-28-19-7-6-17(20(26)24-13-15-4-2-8-22-11-15)10-18(19)21(27)25-14-16-5-3-9-23-12-16/h2-12H,13-14H2,1H3,(H,24,26)(H,25,27)
InChI key
KYWCWBXGRWWINE-UHFFFAOYSA-N
Gene Information
human ... TBXA2R(6915)
Biochem/physiol Actions
Eicosenoid receptor antagonist; a thromboxane A2 antagonist; antiplatelet agent.
Classe de stockage
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
W Van Molle et al.
FEBS letters, 467(2-3), 201-205 (2000-02-17)
Tumor necrosis factor (TNF) induces hepatitis when injected in human beings or in rodents. The molecular mechanism by which TNF induces hepatic distress remains largely unknown, although induction of apoptosis of hepatocytes appears to be an essential step. In order
M Berrettini et al.
European journal of clinical pharmacology, 39(5), 495-500 (1990-01-01)
Picotamide (G 137), a new non prostanoid inhibitor of in vitro arachidonic acid induced platelet aggregation, has been further characterized in in vitro and ex vivo studies. When whole blood was activated with collagen in the presence of picotamide 5
G D'Andrea et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 27 Suppl 2, S96-S99 (2006-05-12)
Migraine with aura (MwA) sufferers, at times, need specific treatments. This is the case when the auras are frequent, prolonged and cause anxiety and distress. Abnormal release of glutamate, which may trigger auras, and abnormal platelet behaviour, which constitutes a